Tackling PD1i resistance in Hodgkin lymphoma

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, comments on the approaches to tackling PD1 inhibitor (PD1i) resistance in patients with Hodgkin lymphoma (HL). Combining a PD1i with an HDAC inhibitor is an approach being trialed, with the rationale being that HDAC inhibition will allow for the re-expression of immune receptors and restore sensitivity to PD1 inhibition. Another strategy involves targeting multiple checkpoints, for example, in the trial investigating the combination of pembrolizumab and favezelimab. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.